Drugs.com - New Drug Approvals

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths

INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yuflyma (adalimumab-aaty), now including prefilled syringe...

May 27, 2025 - 02:50
 0
Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths
INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yuflyma (adalimumab-aaty), now including prefilled syringe...
Read More

Tags:

Previous Article

Data-driven beauty: Challenges remain in supply chain integration and innovation

Next Article

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Tre...

Related Posts

Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Dupixent (dupilumab) Approved in the U.S. as the First ...

May 12, 2025  0

FDA Approves an Updated Label for Tryvio (aprocitentan)...

May 12, 2025  0

FDA Approves Imfinzi (durvalumab) for Muscle Invasive ...

May 12, 2025  0